Track topics on Twitter Track topics that are important to you
UCB Group (Euronext:UCB) reported detailed data from a Phase III trial of Neupro rotigotine in Chinese patients with early stage Parkinson's disease (PD). The company announced top-line results in Feb...
UCB, the Belgian biopharma, reported positive results from a China Phase III trial of its transdermal patch product, NEUPRO®, a treatment for early stage Parkinson's disease. NEUPRO (rotigotine) i...
* Announces first presentation of data from Neupro (rotigotine transdermal patch) phase 3 study in China at international congress
BRUSSELS, April 20, 2015 /PRNewswire/ -- UCB, a global biopharmaceutical company focusing on neurology and immunology treatment and research, is sponsoring a total of 24 data presentations at the...
Recently added to the BioPortfolio report store, Global Neurodegenerative Diseases Market 2015-2019 is a new report from Technavio published on 2015-05-05. This 168-page report is available in pdf fr...